A5037786519- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Economic and Financial Impacts of Cancer
- Multiple and Secondary Primary Cancers
- Radiopharmaceutical Chemistry and Applications
- Cancer, Lipids, and Metabolism
- CNS Lymphoma Diagnosis and Treatment
- Lipoproteins and Cardiovascular Health
- Ferroptosis and cancer prognosis
- Prostate Cancer Treatment and Research
- Global Cancer Incidence and Screening
- Brain Metastases and Treatment
- Long-Term Effects of COVID-19
- T-cell and Retrovirus Studies
- Lung Cancer Treatments and Mutations
- Acute Lymphoblastic Leukemia research
- Recycling and Waste Management Techniques
- Glioma Diagnosis and Treatment
- Reproductive Biology and Fertility
- Mass Spectrometry Techniques and Applications
- Chronic Myeloid Leukemia Treatments
- Extraction and Separation Processes
- COVID-19 Clinical Research Studies
- Complement system in diseases
- Reproductive Health and Technologies
The University of Texas Health Science Center at San Antonio
2020-2024
South Texas Veterans Health Care System
2020-2024
University of California, Irvine Medical Center
2024
University of California, Irvine
2024
The University of Texas at San Antonio
2020
American Public University System
2018
We performed a retrospective chart review of 6266 randomly selected DLBCL patients treated in the VHA nationwide between 1/1/2011 and 12/31/2021. The 3178 who met inclusion criteria were predominantly male (97%) white (75%). Median age diagnosis for Black was 63 years vs 69 entire cohort (
Abstract We present a unique case of 68‐year‐old male who was diagnosed with COVID‐19. His hospital course complicated by widespread thrombosis, renal failure, and thrombocytopenia. Thrombotic thrombocytopenic purpura initially suspected, yet plasma exchange steroids did not improve his disease. Ultimately, he COVID‐19‐induced thrombotic microangiopathy.
e17064 Background: The VISION study demonstrated improved outcomes with up to 6 doses of 177 -Lu-PSMA plus standard-of-care (SOC) therapy versus SOC alone in pre-treated mCRPC patients, which led its regulatory approval on 03/23/22. This is our real-world experience at the University California, Irvine and Hoag Hospital. Methods: a retrospective analysis 22 patients treated Hospital since 03/23/2022. Baseline demographic, pathologic, genomic characteristics all who received (along their...
e17049 Background: 177Lu–PSMA is a radiolabeled small molecule that delivers β radiation to cells expressing prostate-specific membrane antigen (PSMA). It has been approved for use in metastatic castration-resistant prostate cancer (mCPRC) 3/2022, based on VISION study. The Food and Drug Administration (FDA) label requires prior therapy with an androgen receptor pathway inhibitor (ARPI) taxane-based chemotherapy as well presence of at least one PSMA-positive tumor uptake greater than normal...
135 Background: Young adults undergoing cancer treatment often face increased risk of infertility. Despite current ASCO guidelines recommending prompt fertility preservation education, knowledge about prevalence and barriers to oncofertility care is lacking. This particularly true for patients in medically underserved minority communities. study sought characterize the utilization counseling a major Hispanic serving institution. Methods: Retrospective chart review was performed at University...
169 Background: Prostate cancer is the most common in men United States. Death prostate patients often related to other medical conditions and not itself. Hence, it important optimize co-morbidities, such as hyperlipidemia, hypertension, cardiovascular diseases these patients. However, there are numerous studies portraying ability of statins increase progression free survival overall cancer. This has led significant interest having anti-cancer properties ultimately improving long term...
e17612 Background: Prostate cancer is the most common in men United States. Death prostate patients often reported to be non-prostate related, attributed other medical conditions. As associated with a prolonged survival, care of these includes optimizing co-morbidities, such as cardiovascular disease. There are multiple reports and epidemiological studies statins decreasing risk, progression, overall mortality cancer. Previously we had gathered data on 300 diagnosed at VA San Antonio. The...
e17059 Background: Hispanics (HI) are the fastest growing ethnic group in US, representing 52% of US population growth from 2010-2018. In past decade, they have also experienced a rise incidence testicular cancer. Studies shown that HI higher Non-Seminomatous Germ Cell Tumors (NSGCT), present at an earlier age, advanced stage diagnosis, and worse outcomes (including increased mortality) when compared to Non-Hispanics (NH). However, there is paucity data need better characterize this patient...
6526 Background: Racial and ethnic disparities in access to care outcomes are well-established critical issues across several malignancies, including DLBCL. Previous studies from national registry datasets have shown racial DLBCL disease characteristics, treatment outcomes. The VHA is an equal system providing a unique environment investigate cancer the continuum. Methods: This retrospective chart review of 4033 randomly selected patients with ICD code for lymphoma treated within between...
e19567 Background: Peripheral T-cell lymphomas (PCTLs) are an aggressive group of that comprise less than 15% all non-Hodgkin in adults. There is limited literature regarding differences outcomes for Hispanics (H). Some studies indicate worse H compared to non-Hispanics (NH), whereas others have shown comparable outcomes. The purpose this study evaluate demographics, treatment patterns and survival PCTLs among vs. NH Texas (TX) Florida (FL). Methods: This a retrospective analysis patients...